Fludarabine Injection

DRUG4 trials

Sponsors

University of California, San Francisco, Institute of Hematology & Blood Diseases Hospital, China, Medical University of South Carolina, Ruijin Hospital

Conditions

1Q21 AmplificationAML, AdultB-cell Non Hodgkin LymphomaChronic Lymphocytic LeukemiaComplex KaryotypeExtramedullary PlasmacytomaFanconi's AnemiaGenetic Inborn Errors of Metabolism

Phase 1

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

RecruitingNCT05702853

Medical University of South CarolinaB-cell Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia

Start: 2023-11-06End: 2026-12-30Target: 27Updated: 2026-03-27

Phase 3

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Not yet recruitingNCT06297772

Ruijin HospitalAML, Adult

Start: 2024-06-01End: 2028-05-01Target: 220Updated: 2024-06-04

Unknown Phase

Study of Clofarabine and Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation (HCT)

CompletedNCT03609814

University of California, San FranciscoFanconi's Anemia, Genetic Inborn Errors of Metabolism, Hematologic Malignancies +5

Start: 2016-01-26End: 2020-06-30Updated: 2021-10-04

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

Institute of Hematology & Blood Diseases Hospital, China1Q21 Amplification, Complex Karyotype, Extramedullary Plasmacytoma +6

Start: 2018-01-05End: 2020-08-01Target: 50Updated: 2019-07-05